anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
It is known that glycolate, an intermediary molecule in normal metabolism, can be converted into oxalate. The origin of urinary oxalate is of interest as calcium oxalate is a main component of kidney stones. In the rare disease primary hyperoxaluria, excessive production of oxalate by the body results in frequent kidney stones and can cause loss of kidney function. Primary hyperoxaluria is caused by deficiencies in one of several enzymes involved in the glycolate pathway.

This study will seek to determine how much oxalate is formed from glycolate in normal subjects. After consuming a controlled diet, subjects will either ingest or have an intravenous infusion of carbon 13 glycolate, a stable isotope of glycolate that can be tracked and will also label downstream metabolic products. Blood and urine samples will be assessed for their amounts of labeled glycolate and labeled oxalate to provide an accurate measure of how much oxalate is made from normal glycolate breakdown in healthy human subjects.
Participants randomized to receive double-blind placebo at Week 0, Week 4, and Week 16 in Period 1. At Week 24 participants will receive 150 mg risankizumab followed by open-label 150 mg risankizumab at Week 28, and every 12 weeks thereafter in Period 2 until the final dosing time point at Week 316.
PROBLEM TO BE SOLVED: To obtain an antiviral agent excellent in antiviral activity, low in cytotoxicity, comprising gold and a substrate containing gold. SOLUTION: This antiviral agent such as an anti-HIV agent comprises gold/or a gold-containing substrate obtained by supporting a gold compound on a substrate such as calcium phosphate by adsorption and/or ion exchange by a conventional method. The content of gold is 0.1-50wt.%. When a composition comprising gold and the substrate is baked at 300-1,200 deg.C for 0.5-2 hours, properties are stabilized and the composition has low toxicity. The agent can be pharmaceutically manufactured into a dosage form for non-enteral administration, oral administration, rectal administration, dermal administration, local administration or administration through the vagina. A raw material resin for a medical article is kneaded with the agent to provide the resin with antiviral activity or can be made into a molding.  An antiviral effect on viral proliferation effectively and stably manifests by effectively supporting gold on the substrate.
α-Synuclein (αSyn) aggregates, detected in the biofluids of patients with Parkinson's disease (PD), have the ability to catalyze their own aggregation, leading to an increase in the number and size of aggregates. This self-templated amplification is used by newly developed assays to diagnose Parkinson's disease and turns the presence of αSyn aggregates into a biomarker of the disease. It has become evident that αSyn can form fibrils with slightly different structures, called "strains" or polymorphs, but little is known about their differential reactivity in diagnostic assays. Here, we compared the properties of two well-described αSyn polymorphs. Using single-molecule techniques, we observed that one of the polymorphs had an increased tendency to undergo secondary nucleation and we showed that this could explain the differences in reactivity observed in in vitro seed amplification assay and cellular assays. Simulations and high-resolution microscopy suggest that a 100-fold difference in the apparent rate of growth can be generated by a surprisingly low number of secondary nucleation "points" (1 every 2000 monomers added by elongation). When both strains are present in the same seeded reaction, secondary nucleation displaces proportions dramatically and causes a single strain to dominate the reaction as the major end product.
The BM aspirate will be diluted at 6:1 ratio with phosphate buffer saline with 2 ml EDTA (30 ml BM aspirate+ 5 ml PBS/EDTA buffer).MNCs will be separated under aseptic conditions using a Ficoll. Hypaque desity gradient by centrifugation at 1800 rpm for 20 min then the MNCs will be plated in 40 ml(αMEM), serum free media; mesencult(MSCs culture),penicillin (100 U/ml),streptomycin(10 mg/ml),0.5 ml amphotericin B(all from Gibco BRL) and 10 ng/ml basic fibroblast growth factor (b-FGF)(R\&D system, Minneapolis, MN) and will be incubated at 370 c in a humidified atmosphere containing 5% CO2 .after one day ,nonadherent cells will be cultured in the presence of Mesenchymal media for 3 weeks changed every week. After reaching 80% confluence the MSCs will be placed in 10 ml saline and infused IV.
Patients receive tocilizumab IV on day -7 of cycle 1, and on day 1 of subsequent cycles. Patients also receive venetoclax PO on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Consciousness is one of the most complex aspects of human experience. Studying the mechanisms involved in the transitions among different levels of consciousness remains as one of the greatest challenges in neuroscience. In this study we use a measure of integrated information (ΦAR) to evaluate dynamic changes during consciousness transitions. We applied the measure to intracranial electroencephalography (SEEG) recordings collected from 6 patients that suffer from refractory epilepsy, taking into account inter-ictal, pre-ictal and ictal periods. We analyzed the dynamical evolution of ΦAR in groups of electrode contacts outside the epileptogenic region and compared it with the Consciousness Seizure Scale (CCS). We show that changes on ΦAR are significantly correlated with changes in the reported states of consciousness.
The invention discloses a novel molecular target for aspirin to play a role in neuroprotection on cerebral apoplexy. Aspirin exerts neuroprotective effects on stroke-model mice by acetylation of the intracellular calcium ion-calmodulin dependent protein kinase 2α (CaMK 2 α). The invention clarifies a new mechanism of aspirin to exert neuroprotective effect independent of its anticoagulant function. The invention also discloses that aspirin derivatives can also exert neuroprotective effect on mice with cerebral apoplexy types through acetylation of CaMK2 alpha, but the anticoagulation effect and bleeding risk of the aspirin derivatives are weaker than those of aspirin. The invention also discloses a safe and effective new strategy for preventing cerebral apoplexy: through modifying aspirin, the anticoagulant activity of aspirin is reduced, but the function of the aspirin in the acetylation of CaMK2 alpha is reserved, so that the neuroprotection effect of preventing cerebral apoplexy can be better exerted, and the side effect of bleeding is reduced. The invention provides a safer and more effective way for the preventive medication of cerebral ischemia diseases.
A polymer-drug conjugate of Formula I for delivery of therapeutic agents; Wherein R1, R2 and R3 are independently selected from H or methyl; x and y are independently a number between 1-100; n is a number between 1-50; L is a cleavable linker; A and B are independently an end group or null; and D is a therapeutic agent slected from combretasatin, 5-fluorouracil, gemcitabine, chlorquine, and doxorubicin. The linker may be selected from a polyethylene glycol, an amino acid, poly amino acids, short peptides and an optionally substituted C1-10 hydrocarbon comprising a physiologically labile functional group. Polymeric assemblies formed with polymer drug conjugates of Formula I are claimed. The polymeric assembly may encapsulate additional therapeutic agents. Methods of preparing a polymer drug conjugate of Claim 1 are also claimed wherein the methods first comprise polymerizing a PEG grafted or PEG methyl ester grafted acrylate or methacrylate monomer to form a brush block copolymer. Pharmaceutical compositions comprising the polymer drug conjugate or polymeric assemblies thereof are also claimed. Claims to the polymer drug conjugate, polymeric assemblies and compositions thereof for use in the treatment or prophylaxis of cancer are also provided.
Participants receive MK-3475A (pembrolizumab Conc1 \[dose 1\] + MK-5180) SC on Day 1 of Cycles 1 and 3 plus 400 mg pembrolizumab intravenously (IV) on Day 1 of Cycles 2 and 4 to 18, with or without background standard of care (SOC) chemotherapy as appropriate for the indication. A cycle is 42 days.
A total of 44 healthy and trained volunteers, age between 18 and 70 years. Subjects must have basic mountaineering experience.
A product for use as surgical or dental prostheses or in dental repairs is made by intimately incorporating a solid after-halogenated polyvinyl halide or after-halogenated copolymer containing vinyl halide groups, with a liquid polymerisable vinyl compound in which the solid polymerisate is swellable and which consists wholly or mainly of methyl methacrylate, and polymerizing the liquid in the presence of a catalyst.  The halogenated polymer is preferably after-chlorinated polyvinyl chloride and should be in a swellable form.  This may be obtained by swelling in acetone, drying in vacuo and grinding and sifting the loosened mass; or precipitating from a cooled and gelled solution with a non-solvent; or by cutting up extruded filaments into short lengths.  Other compounds which may be added to the methyl methacrylate include butyl acrylate, ethyl acrylate and octyl methacrylate.  Specified catalysts are benzoyl peroxide and toluene sulphinic acid.  Pigments such as cadmium red and titanium dioxide may be added to the compositions which are moulded in plaster or gypsum moulds.  Specifications 401,200 and 484,343 are referred to.
BACKGROUND: While it has been hypothesized that high plaque stress and strain may be related to plaque rupture, its direct verification using in vivo coronary plaque rupture data and full 3-dimensional fluid-structure interaction models is lacking in the current literature due to difficulty in obtaining in vivo plaque rupture imaging data from patients with acute coronary syndrome. This case-control study aims to use high-resolution optical coherence tomography-verified in vivo plaque rupture data and 3-dimensional fluid-structure interaction models to seek direct evidence for the high plaque stress/strain hypothesis.
METHODS: In vivo coronary plaque optical coherence tomography data (5 ruptured plaques, 5 no-rupture plaques) were acquired from patients using a protocol approved by the local institutional review board with informed consent obtained. The ruptured caps were reconstructed to their prerupture morphology using neighboring plaque cap and vessel geometries. Optical coherence tomography-based 3-dimensional fluid-structure interaction models were constructed to obtain plaque stress, strain, and flow shear stress data for comparative analysis. The rank-sum test in the nonparametric test was used for statistical analysis.
RESULTS: Our results showed that the average maximum cap stress and strain values of ruptured plaques were 142% (457.70 versus 189.22 kPa; P=0.0278) and 48% (0.2267 versus 0.1527 kPa; P=0.0476) higher than that for no-rupture plaques, respectively. The mean values of maximum flow shear stresses for ruptured and no-rupture plaques were 145.02 dyn/cm2 and 81.92 dyn/cm2 (P=0.1111), respectively. However, the flow shear stress difference was not statistically significant.
CONCLUSIONS: This preliminary case-control study showed that the ruptured plaque group had higher mean maximum stress and strain values. Due to our small study size, larger scale studies are needed to further validate our findings.
PROBLEM TO BE SOLVED: To obtain an inflammatory respiratory disease therapeutic agent which shows an infiltration inhibitory effect on neutrophils by including a lactone derivative as an active ingredient. SOLUTION: This inflammatory respiratory disease therapeutic agent is obtained by including a lactone derivative (e.g. 1α,25-dihydroxyvitamin D3-26,23- lactone or the like) represented by the formula [(m) and (n) are each 0 or 1] or its solvated substance as an active ingredient. It is favorable that the daily dose of the above active ingredient is usually 0.001-100 μg divided into 1-3 portions. Further, as the objective disease for the above therapeutic agent, acute upper respiratory tract infection (e.g. common cold, acute rhinitis, acute tonsillitis or the like), chronic sinusitis, allergic rhinitis, chronic lower respiratory tract infection (e.g. chronic bronchitis or the like), pulmonary emphysema, pneumonia, bronchial asthma, pulmonary tuberculosis sequelle, acute respiratory distress syndrome, cystic fibrosis and pulmonary fibrosis are illustrated.
The experimental group not only have the routine treatment, but have acupressure when they back to the ward with the following 3 days . The effectiveness evaluation was carried out by the same researcher before and after intervention. There are three assessments in this study: primary outcome including postoperative pain and bowel movement. The short-form McGill Pain Questionnaire is used to measure the quality of pain, Visual Analog Scale is used to the pain intensity and stethoscope is used to listen to the bowel sound. The study, also, will be recorded postoperative exhaust time, the postoperative date of Indwelling drainage tube and postoperative length of stay.
BACKGROUND: Epilepsy is a common neurological disorder that affects approximately 60 million people worldwide. Characterized by unpredictable neural electrical activity abnormalities, it results in seizures with varying intensity levels. Electroencephalography (EEG), as a crucial technology for monitoring and predicting epileptic seizures, plays an essential role in improving the quality of life for people with epilepsy.
METHOD: This study introduces an innovative deep learning model, a lightweight triscale yielding convolutional neural network" (LTY-CNN), that is specifically designed for EEG signal analysis. The model integrates a parallel convolutional structure with a multihead attention mechanism to capture complex EEG signal features across multiple scales and enhance the efficiency achieved when processing time series data. The lightweight design of the LTY-CNN enables it to maintain high performance in environments with limited computational resources while preserving the interpretability and maintainability of the model.
RESULTS: In tests conducted on the SWEC-ETHZ and CHB-MIT datasets, the LTY-CNN demonstrated outstanding performance. On the SWEC-ETHZ dataset, the LTY-CNN achieved an accuracy of 99.9%, an area under the receiver operating characteristic curve (AUROC) of 0.99, a sensitivity of 99.9%, and a specificity of 98.8%. Furthermore, on the CHB-MIT dataset, it recorded an accuracy of 99%, an AUROC of 0.932, a sensitivity of 99.1%, and a specificity of 93.2%. These results signify the remarkable ability of the LTY-CNN to distinguish between epileptic seizures and nonseizure events. Compared to other existing epilepsy detection classifiers, the LTY-CNN attained higher accuracy and sensitivity.
CONCLUSION: The high accuracy and sensitivity of the LTY-CNN model demonstrate its significant potential for epilepsy management, particularly in terms of predicting and mitigating epileptic seizures. Its value in personalized treatments and widespread clinical applications reflects the broad prospects of deep learning in the health care sector. This also highlights the crucial role of technological innovation in enhancing the quality of life experienced by patients.
This is a multicenter, un-blinded, open label, pivotal supplemental study to G130163 intended to evaluate the safety and efficacy of treating previous sham subjects in the Essential pivotal trial (IDE#G130163) with the active treatment (the placement of g-Cath EZ suture anchors along with diet and exercise). Compliant sham subjects (those who attended all primary IDE follow-up visits AND who continue to meet eligibility criteria as described in this protocol) will be offered this active treatment after their 12 month unblinding visit in the Essential pivotal trial.

This supplemental study will consist of up to an 8 week screening period after each subject's unblinding visit, an enrollment (active treatment) day, and a 12-month follow-up period. All sham subjects in the Essential Trial (total quantity of one hundred eleven (111) subjects) are planned for enrollment, but the total quantity of sham subjects provided the active treatment will depend on the number of subjects who are compliant. The active treatment will be provided by the original investigator for that subject at the same investigational center (one of the original 11) used in the Essential trial. Collection of data will be accomplished by utilizing independent nutritionists/clinical research nurses to administer the diet/exercise plan and collect weight loss efficacy assessments. Efficacy assessments will also include changes in select co-morbidities, quality of life assessments, and changes in hunger and satiety, among others. Safety assessments include subject and investigator reported adverse events, physician follow-up assessments, and blood pressure measurements.
Participants received evolocumab 420 mg once a month plus standard of care for the first year of the study (SOC-controlled period). At week 52 participants continued treatment with evolocumab 420 mg QM for another 4 years during the all-IP period.
1477518 Antibiotic E ROSENBERG 28 June 1974 [10 July 1973] 28932/74 Heading C2A A process for preparing novel antibiotic TA comprises cultivating a suitable strain of Myxococcus xanthus under aerobic conditions until a material having substantial antibiotic activity is produced. Antibiotic TA has a # max of 242 nm. in methanol, an IR spectrum indicated in Fig. 4 (not shown), is soluble in chloroform and methanol, is a white solid and has Rf values as defined in Fig. III (not shown). Suitable strains are Myxococcus xanthus TA and Myxococcus xanthus FB (A.T.C.C. No. 25232). The culture medium may contain a pancreatic digest of casein and magnesium sulphate.
Background: Primary biliary cirrhosis is a chronic cholestatic liver disorder which may lead to end stage liver disease causing death or requiring liver transplantation. Additionally, a significant proportion of patients suffers from complications related to impaired bile secretion such as intractable pruritus, chronic fatigue, osteoporosis or lipid disturbance. They all have a significant consequence for patients well being, quality of life and economical aspects of health care systems. Pathogenesis of PBC remains to be fully elucidated. Recent studies show,that chronic liver diseases are associated with an acquired deficiency of S-adenosyl-L-methionine synthetase, an enzyme responsible for the synthesis of SAMe from methionine. SAMe initiates two very important protective metabolic pathways: transmethylation and transsulphuration. As a result of the later, glutathione, taurine and sulphate group are synthesized. Thus SAMe deficiency is associated with impaired detoxification and hepatoprotection and exacerbate liver injury. Supplementation with SAMe has proven useful in alcoholic liver disease, obstetric cholestasis and elimination of hepatitis C virus (HCV). The investigators' studies on experimental models where cholestasis was induced in vitro with lithocholic acid and 17-beta estradiol glucuronide showed that supplementation with SAMe exerts a significant anticholestatic effect. Interestingly, simultaneous administration of SAMe and ursodeoxycholic acid (UDCA) exerts an additive effect.

Methods: The study group will include 20 patients PBC diagnosed with EASL criteria, who have been already treated with UDCA. They will receive UDCA in the dose of 13 - 15mg/kg bw plus SAMe in the dose of 1600 mg bd over the period of 6 months.

The key aim of the project is to analyze the effect of SAMe on the health related quality of life and liver biochemistry. Blood and urine samples (from 24hr urine collection) will be collected for liver biochemistry and metabolites of bile acids. Additionally transient elastography will be performed before and after 6 months SAMe treatment.
Revefenacin is a long-acting muscarinic antagonist, which is often referred to as an anticholinergic. It has similar affinity to the subtypes of muscarinic receptors M1 to M5. In the airways, it exhibits pharmacological effects through inhibition of M3 receptor at the smooth muscle leading to bronchodilation. The competitive and reversible nature of antagonism was shown with human and animal origin receptors and isolated organ preparations. In preclinical in vitro as well as in vivo models, prevention of methacholine- and acetylcholine-induced bronchoconstrictive effects was dose-dependent and lasted longer than 24 hours. The clinical relevance of these findings is unknown. The bronchodilation following inhalation of revefenacin is predominantly a site-specific effect.
Mycophenolate mofetil capsules taken orally twice a day (in the morning and in the evening) at the dose the participant was taking prior to study start + Placebo to mycophenolate sodium tablets taken twice a day for 30 days. Participants remained on their standard immunosuppressive regimen of calcineurin inhibitors (CNI) (Cyclosporin A or Tacrolimus) administered with or without corticosteroids throughout the study.
This 8-week program will meet once per week for 1.5 hours. Participants will be trained in performing various cognition enhancing techniques at each class, and will practice these techniques both in class and at home each day for 45 minutes.
The study aimed to examine the relationship between the quality of life, life satisfaction and anxiety levels of wheelchair basketball players. This study was carried out with wheelchair basketball players in Istanbul between March 2022 and May 2022. Twenty-three wheelchair basketball players were included in the study. The scope of the study was explained to the wheelchair basketball players who participated in the study during the face-to-face interview, and the consent forms prepared by the researcher were distributed. The participants, who approved the consent form and agreed to participate in the study, had to fill out the sociodemographic form. The quality of life of the participants was determined by the SF-12 Quality of Life Scale; Satisfaction with life was evaluated with the Satisfaction with Life Scale, and anxiety levels were evaluated with the Beck Anxiety Scale. Statistics were performed using SPSS Version 22.0 program.